# Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML

> **NCT02109627** · PHASE1 · TERMINATED · sponsor: **C. Babis Andreadis** · enrollment: 17 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Relapsed Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** Ficlatuzumab
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT02109627
- **Lead sponsor:** C. Babis Andreadis
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05-01
- **Primary completion:** 2019-12-02
- **Final completion:** 2019-12-02
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Low Accrual
- **Last updated:** 2020-03-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02109627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02109627, "Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02109627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*